Foghorn Therapeutics Shifts Focus from Development Of Cancer Hopeful with Eye Cancer
Foghorn Therapeutics Inc (NASDAQ: FHTX) announced the data from the Phase 1 dose escalation safety study of FHD-286 in metastatic uveal melanoma (mUM). These findings further validate the safety and tolerability profile of FHD-286. However, Foghorn does not intend to pursue FHD-286 to treat uveal melanoma. The Phase 1 dose-escalation study of FHD-286 in metastatic uveal melanoma included 73 patients who had received a median of two prior therapies across nine different cohorts. The clinical data
Source: yahoo.com